194 related articles for article (PubMed ID: 26097540)
1. LRIG1 enhances the radiosensitivity of radioresistant human glioblastoma U251 cells via attenuation of the EGFR/Akt signaling pathway.
Yang JA; Liu BH; Shao LM; Guo ZT; Yang Q; Wu LQ; Ji BW; Zhu XN; Zhang SQ; Li CJ; Chen QX
Int J Clin Exp Pathol; 2015; 8(4):3580-90. PubMed ID: 26097540
[TBL] [Abstract][Full Text] [Related]
2. Overexpressed miR-183 promoted glioblastoma radioresistance via down-regulating LRIG1.
Fan H; Yuan R; Cheng S; Xiong K; Zhu X; Zhang Y
Biomed Pharmacother; 2018 Jan; 97():1554-1563. PubMed ID: 29793318
[TBL] [Abstract][Full Text] [Related]
3. LRIG1 dictates the chemo-sensitivity of temozolomide (TMZ) in U251 glioblastoma cells via down-regulation of EGFR/topoisomerase-2/Bcl-2.
Qi XC; Xie DJ; Yan QF; Wang YR; Zhu YX; Qian C; Yang SX
Biochem Biophys Res Commun; 2013 Aug; 437(4):565-72. PubMed ID: 23850692
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of microRNA-4295 enhances cisplatin-induced gastric cancer cell apoptosis through the EGFR/PI3K/Akt signaling pathway by targeting LRIG1.
Yan R; Li K; Yuan DW; Wang HN; Zhang Y; Dang CX; Zhu K
Int J Oncol; 2018 Dec; 53(6):2566-2578. PubMed ID: 30320337
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of LRIG1 expression by RNA interference promotes the aggressive properties of glioma cells via EGFR/Akt/c-Myc activation.
Xie R; Yang H; Xiao Q; Mao F; Zhang S; Ye F; Wan F; Wang B; Lei T; Guo D
Oncol Rep; 2013 Jan; 29(1):177-84. PubMed ID: 23124613
[TBL] [Abstract][Full Text] [Related]
6. Soluble LRIG2 ectodomain is released from glioblastoma cells and promotes the proliferation and inhibits the apoptosis of glioblastoma cells in vitro and in vivo in a similar manner to the full-length LRIG2.
Xiao Q; Tan Y; Guo Y; Yang H; Mao F; Xie R; Wang B; Lei T; Guo D
PLoS One; 2014; 9(10):e111419. PubMed ID: 25353163
[TBL] [Abstract][Full Text] [Related]
7. LRIG1, human EGFR inhibitor, reverses multidrug resistance through modulation of ABCB1 and ABCG2.
Liu B; Guo Z; Dong H; Daofeng T; Cai Q; Ji B; Zhang S; Wu L; Wang J; Wang L; Zhu X; Liu Y; Chen Q
Brain Res; 2015 Jun; 1611():93-100. PubMed ID: 25801120
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus-mediated LRIG1 expression enhances the chemosensitivity of bladder cancer cells to cisplatin.
Yan Z; Jiang J; Li F; Yang W; Xie G; Zhou C; Xia S; Cheng Y
Oncol Rep; 2015 Apr; 33(4):1791-8. PubMed ID: 25695283
[TBL] [Abstract][Full Text] [Related]
9. EGFRvIII does not affect radiosensitivity with or without gefitinib treatment in glioblastoma cells.
Struve N; Riedel M; Schulte A; Rieckmann T; Grob TJ; Gal A; Rothkamm K; Lamszus K; Petersen C; Dikomey E; Kriegs M
Oncotarget; 2015 Oct; 6(32):33867-77. PubMed ID: 26418954
[TBL] [Abstract][Full Text] [Related]
10. MicroRNA-590-3p enhances the radioresistance in glioblastoma cells by targeting LRIG1.
Chen L; Wang W; Zhu S; Jin X; Wang J; Zhu J; Zhou Y
Exp Ther Med; 2017 Aug; 14(2):1818-1824. PubMed ID: 28810655
[TBL] [Abstract][Full Text] [Related]
11. LRIG1 improves chemosensitivity through inhibition of BCL-2 and MnSOD in glioblastoma.
Ding J; Liu B; He Y; Yuan X; Tian D; Ji B; Wang L; Wu L; Dong H; Wang J; Zhu X; Cai Q; Zhang S; Chen Q
Cell Biochem Biophys; 2015 Jan; 71(1):27-33. PubMed ID: 25449296
[TBL] [Abstract][Full Text] [Related]
12. LRIG1 inhibits hypoxia-induced vasculogenic mimicry formation via suppression of the EGFR/PI3K/AKT pathway and epithelial-to-mesenchymal transition in human glioma SHG-44 cells.
Zhang X; Song Q; Wei C; Qu J
Cell Stress Chaperones; 2015 Jul; 20(4):631-41. PubMed ID: 25860915
[TBL] [Abstract][Full Text] [Related]
13. LRIG1 enhances cisplatin sensitivity of glioma cell lines.
Wang X; Xiao Q; Xing X; Tian C; Zhang H; Ye F; Wan F; Wang B; Guo D; Lei T
Oncol Res; 2012; 20(5-6):205-11. PubMed ID: 23581227
[TBL] [Abstract][Full Text] [Related]
14. Resveratrol inhibits glioma cell growth via targeting LRIG1.
Liu L; Zhang Y; Zhu K; Song L; Tao M; Huang P; Pan Y
J BUON; 2018; 23(2):403-409. PubMed ID: 29745084
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Cathepsin D (CTSD) enhances radiosensitivity of glioblastoma cells by attenuating autophagy.
Zheng W; Chen Q; Wang C; Yao D; Zhu L; Pan Y; Zhang J; Bai Y; Shao C
Mol Carcinog; 2020 Jun; 59(6):651-660. PubMed ID: 32253787
[TBL] [Abstract][Full Text] [Related]
16. Over-expression of LRIG1 suppresses biological function of pituitary adenoma via attenuation of PI3K/AKT and Ras/Raf/ERK pathways in vivo and in vitro.
Cheng SQ; Fan HY; Xu X; Gao WW; Lv SG; Ye MH; Wu MJ; Shen XL; Cheng ZJ; Zhu XG; Zhang Y
J Huazhong Univ Sci Technolog Med Sci; 2016 Aug; 36(4):558-563. PubMed ID: 27465333
[TBL] [Abstract][Full Text] [Related]
17. Down-regulation of leucine-rich repeats and immunoglobulin-like domain proteins (LRIG1-3) in HP75 pituitary adenoma cell line.
Guo D; Han L; Shu K; Chen J; Lei T
J Huazhong Univ Sci Technolog Med Sci; 2007 Feb; 27(1):91-4. PubMed ID: 17393120
[TBL] [Abstract][Full Text] [Related]
18. LRIG1, a 3p tumor suppressor, represses EGFR signaling and is a novel epigenetic silenced gene in colorectal cancer.
Kou C; Zhou T; Han X; Zhuang H; Qian H
Biochem Biophys Res Commun; 2015 Aug; 464(2):519-25. PubMed ID: 26159916
[TBL] [Abstract][Full Text] [Related]
19. LRIG1 combined with cisplatin enhances bladder cancer lesions via a novel pathway.
Li F; Yang W; Guo D; Hu Z; Xu H; Ye Z
Oncol Rep; 2011 Jun; 25(6):1629-37. PubMed ID: 21431282
[TBL] [Abstract][Full Text] [Related]
20. [Molecular mechanism of LRIG1 cDNA-induced apoptosis in human glioma cell line H4].
Ye F; Guo DS; Niu HQ; Tao SZ; Ou YB; Lu YP; Lei T
Ai Zheng; 2004 Oct; 23(10):1149-54. PubMed ID: 15473925
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]